June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Therapeutic potential of a novel isoquinoline sulfonamide derivative with protein kinase inhibition function, H-1337, in wet AMD
Author Affiliations & Notes
  • Masahiko Sugimoto
    Human Research Promotion and Drug Development, Mie University, Tsu, Japan
    Ophthalmology, Mie University School of Medicine, Tsu, Japan
  • Mineo Kondo
    Human Research Promotion and Drug Development, Mie University, Tsu, Japan
    Ophthalmology, Mie University School of Medicine, Tsu, Japan
  • Yoko Yoshida
    Human Research Promotion and Drug Development, Mie University, Tsu, Japan
    D. Western Therapeutics Institute, Inc., Nagoya, Japan
  • Hitomi Tanimoto
    Human Research Promotion and Drug Development, Mie University, Tsu, Japan
    D. Western Therapeutics Institute, Inc., Nagoya, Japan
  • Ryohei Nakamura
    Human Research Promotion and Drug Development, Mie University, Tsu, Japan
    D. Western Therapeutics Institute, Inc., Nagoya, Japan
  • Hiroyoshi Hidaka
    Human Research Promotion and Drug Development, Mie University, Tsu, Japan
    D. Western Therapeutics Institute, Inc., Nagoya, Japan
  • Footnotes
    Commercial Relationships Masahiko Sugimoto, D. Western Therapeutics Institute, Inc. (F); Mineo Kondo, D. Western Therapeutics Institute, Inc. (F); Yoko Yoshida, D. Western Therapeutics Institute, Inc. (E); Hitomi Tanimoto, D. Western Therapeutics Institute, Inc. (E); Ryohei Nakamura, D. Western Therapeutics Institute, Inc. (E); Hiroyoshi Hidaka, D. Western Therapeutics Institute, Inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 150. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Masahiko Sugimoto, Mineo Kondo, Yoko Yoshida, Hitomi Tanimoto, Ryohei Nakamura, Hiroyoshi Hidaka; Therapeutic potential of a novel isoquinoline sulfonamide derivative with protein kinase inhibition function, H-1337, in wet AMD. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):150.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Exudative age-related macular degeneration (wet AMD) causes vision loss due to choroidal neovascularization (CNV). Here, we investigated the potential of a novel isoquinoline sulfonamide derivative, H-1337, and its main metabolite (H-1337M1), in ex vivo and an experimental CNV model as a potential therapeutic agent for wet AMD.

Methods: H-1337M1 was obtained from incubation of H-1337 with rabbit liver S9 fraction. ARPE-19 cells were pretreated with H-1337 or H-1337 M1 (1 μM for 25 h) and vascular endothelial growth factor (VEGF) concentration in culture supernatant was measured using ELISA. Cell migration was also assessed by wound healing assay. Cell proliferation was assessed by Cell Counting Kit-8 assay under same condition for human retinal microvascular endothelial cells (hRMECs) and human umbilical vascular endothelial cells (HUVEC). Effects of H-1337M1 on CNV were investigated in a rat laser-induced CNV model (6- to 10-week-old Brown Norway rats). After laser photocoagulation, H-1337M1 (intravitreal injections, 15 ng/eye, day 0 and day 7) was administered. Fluorescein angiography (FA) was performed after 2 wks and signal intensities in each laser spot were evaluated using Image J software.

Results: Both H-1337 and H-1337M1 significantly reduced VEGF secretion by 28% and 38%, respectively (p < 0.01 compared with vehicle) and also inhibited cell proliferation of hRMECs (H-1337: with an IC50 of 4.3 μM, H-1337M1: with an IC50 of 4.4 μM) and HUVEC (H-1337: with an IC50 of 3.7 μM, H-1337M1: with an IC50 of 9.2 μM). Cell migration was significantly inhibited by H-1337 (at 30 μM, p < 0.001 compared with vehicle) and H-1337M1 (at 10 μM, p < 0.001 compared with vehicle). The intensities of FA leakage from CNV were also significantly reduced in H-1337M1-treated rats by 67% (p < 0.05 compared with vehicle).

Conclusions: H-1337 and H-1337M1 treatment has the potential to become a novel therapeutic strategy for wet AMD.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×